– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – ...

Cancer is a diagnosis that no one wants to hear. Anyone who has survived cancer themselves or who has watched a loved one ...

Leavenworth’s contributions bridge laboratory research with clinical applications, paving the way for innovative cancer ...

(Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor ...

LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the potential for new therapeutic approaches. As the researchers demonstrate ...

Salk Institute researchers have identified that the protein BCL6 is key in maintaining muscle mass. Their research in mice revealed that boosting BCL6 levels restores muscle mass and strength ...

A new study suggests protein could help you lose fat without sacrificing muscle mass, offering hope for those looking to maintain muscle while shedding pounds. Read the full story here Radhika ...

Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an ...

Introduction: Increased T cell infiltration and interferon gamma (IFNγ) pathway activation are seen in tumors of melanoma patients who respond to ICI (immune checkpoint inhibitor) or MAPK pathway ...

To find out more, Sommars et al. studied the repressor BCL6 in mouse liver cells. The results revealed that BCL6 interacts with hundreds of the same genes as PPAR alpha. When the mice were eating, ...